Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 9/20 | 0.46 |
| ▸ | THRB | P10828 | 12/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20978822 | 0.81 | NPC1 (0.48) | NPC1RAB9AATMLMNACYP1A2 | |
| SCHEMBL20150202 | 0.80 | NPC1 (0.47) | NPC1RAB9AATMLMNACYP1A2 | |
| SCHEMBL20150216 | 0.78 | VCAM1 (0.55) | NPC1ATMVCAM1MAPTHTT | |
| SCHEMBL18113472 | 0.78 | CASP6 (0.62) | VCAM1LMNAPOLB | |
| SCHEMBL21538816 | 0.72 | ALDH1A1 (0.46) | VCAM1MAPTTHRATHRBALDH1A1 | |
| SCHEMBL11498444 | 0.71 | CA1 (0.60) | NPC1RAB9AATMLMNAMAPT | |
| SCHEMBL18496587 | 0.71 | HTT (0.55) | NPC1RAB9AATMLMNAMAPT | |
| SCHEMBL2759010 | 0.71 | NPC1 (0.61) | NPC1RAB9AATMLMNACYP2C19 | |
| SCHEMBL5940574 | 0.70 | MAPT (0.63) | NPC1RAB9AVCAM1LMNACYP1A2 | |
| SCHEMBL6415835 | 0.70 | MAPT (0.55) | NPC1RAB9AATMLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NPC1 4595/4885RAB9A 3462/4885ATM 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.